Meperidine Hydrochloride Inj · #35 of 35 active shortages by FDA posting duration
Brand: DEMEROL
FDA lists Meperidine Hydrochloride Inj as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Unavailable
Meperidine Hydrochloride Injection: Active Shortage
Unavailable 10 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Meperidine Hydrochloride Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)
- Package NDC
- 0409-1176-30
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- May 30, 2025
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Analgesia/Addiction
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay
Full Drug Profile
meperidine
Side effects, interactions, warnings & more
Nearby, Other Meperidine Shortage Records
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Meperidine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay. General shortage guidance lives on the tracker hub.